Analysis of the Impact of Vaccination as Control Strategy of Dengue Transmission Dynamics Considering a Multi-Strain Model
Ana
Kurauchi1, Helio
Junji Shimozako1,2*, Eduardo Massad1,3
1School of
Medicine, University of São Paulo, and LIM01-HCFMUSP,
São Paulo, Brazil
2NeuroMat -Research, Innovation and
Dissemination Center for Neuro mathematics, University of São Paulo, São Paulo,
Brazil
3School of Applied
Mathematics, Fundação Getúlio Vargas, Rio de
Janeiro, Brazil
*Corresponding authors: Helio Junji Shimozako, NeuroMat -Research, Innovation and Dissemination Center for Neuro mathematics, University of São Paulo, São Paulo, Brazil. Email: hjunji21@usp.br
Received Date: 18 August,
2018; Accepted Date: 06 September, 2018; Published Date: 12
September, 2018
Citation: Kurauchi A, Shimozako HJ, Massad E (2018) Analysis of the Impact of Vaccination as Control Strategy of Dengue Transmission Dynamics Considering a Multi-Strain Model. J Vaccines Immunol 2018: 134. DOI: 10.29011/2575-789X.000134
Optimizing a
strategy for Dengue control based on vaccination is very challenging, since the
dynamics of Dengue can be influenced by the coexistence of more than one
serotype (DENV-1, DENV-2, DENV-3 and DENV-4), allowing the appearance of
heterologous infections. In addition, although the effect of cross-immunity
lasts a short period, the real protective power of the immune response is still
not entirely clear. The aim of this study is to develop an optimization model
to control Dengue transmission considering a multi-strain model. In order to
evaluate such optimization, the vaccination was considered the control
strategy. The Dengue dynamics was modeled according to that one developed by [1]. This model considered a human population, which
can be infected by two strains of Dengue virus (strain 1 and 2). Both strains
are simultaneously present in the system and they determine 10 categories in
human population: susceptible to strains 1 and 2 (
2.
Keywords: Dengue; Mathematical Model; Optimal Control;
Vaccine
1. Introduction
In the last years, the estimations of the number of dengue cases (symptomatic or not) have been three times higher than those of the World Health Organization (WHO). The increase on such estimations has occurred not only due to human and/or geographical changes [2,3]. This discrepancy in such estimations has occurred due to biases related to (i) diagnosis processes (failure or imprecision) and (ii) unreported dengue cases. Consequently, the evaluation of the efficacy of potential vaccines is impaired, since its real impact is masked by such biases [4-6]. Considering the difficulty of evaluating the real impact of vaccination and the optimal strategy of its application, an interesting alternative would be the use of mathematical models. The use of mathematical models has been described in studies related to infectious diseases dynamics [7]. Regarding the evaluation of the dengue vaccine, the mathematical model can be a powerful tool to reach the optimization model for a strategy that considers the maximum between the reduction of the incidence of cases and the availability of resources. And, optimizing a strategy for dengue control based on vaccination is very challenging, since the dynamics of dengue can be influenced by the coexistence of more than one serotype (DENV-1, DENV-2, DENV-3 and DENV-4), allowing the appearance of heterologous infections. In addition, although the effect of cross-immunity lasts a short period, the real protective power of the immune response is still not entirely clear [8]. Similarly, the risk of heterologous infections and the uncertainty of the protective power of the immune response have also been reported in the studies about the impact of the dengue vaccine. As an example, it was observed that vaccination in seropositive individuals reduces the risk of hospitalization or symptomatology. However, all dengue vaccine models (produced by Sanofi®) applied to susceptible individuals have shown that they may increase the risk of dengue outbreaks [9,10].
According to Health Ministry/Minister’s Office (MH/MO) Ordinance no. 204 (2016 February 17th), the reporting cases of dengue fever is compulsory in Brazil. Such data are available at Brazilian Health System Data (DATASUS) [11] and the most recent data refers to 2017 year. The Ministry of Health is the first authority concerning to public health and medical processes. According to such data, the number of cases has been increasing over time. Therefore, those data are a good reference to understand the epidemiological scenery about dengue in Brazil. This fact is directly related to consequences in terms of epidemiology and economy. In simple words, infected people are sources of infection and they reduce the workforce, and also increase the public costs due to medicines and treatments. Although this is a simple way to think about this problem (other variables may interfere too), it illustrates the impact of dengue in the society. In addition to the increase of cases, studies have been carried out in order to develop a vaccine which (1) is effective and safe for dengue, (2) provides immunity against the 4 serotypes and (3) is durable. Although the best animal model is the rhesus monkey, there still are some details that make the correlation between clinical research findings and the respective conduct in humans harder [12,13]. Considering this context, the development of a mathematical model in order to study the impact of vaccination emerges as an alternative to the ethical question (since the use of living beings for experimentation would be avoided) and to estimate quantitative indexes for the impact of the vaccine in the epidemiological, social and economic approaches [6].
The aim of this study is to develop an optimization model to control dengue transmission considering a multi-strain model. In order to evaluate such optimization, the vaccination was considered the control strategy. Here, the vaccine model produced by Sanofi® (which is recommended by World Health Organization) was taken as reference to the simulations. Therefore, it is expected to evaluate the epidemiologic impact of dengue vaccination as preventive control strategy.
2.
The Model
Firstly, the mathematical model presented in this project is an adaptation of that one proposed by Santos in her doctoral thesis [1], and also added some conceptions from [14-16]. Thus, in this project, it is considered:
I.A human population, which is constant over time, is divided into ten
classes: (i) susceptible to strains
II.Individuals from
III.The infection by one serotype confers life-long immunity to that
serotype;
IV.The human population is homogeneously in contact with two strains of
dengue fever;
The complete system of ordinary differential equations for the two-strain
epidemiological system is given by system (1) and the dynamics is described as
follows. Susceptible individuals to both strains (
No epidemiological asymmetry between strains is assumed, i.e. infections
with strain
The process of model analysis and results interpretation will be similar to that one developed by [14,16,26,27].
3.
The Reported
Cases
In Brazil, reporting cases of Dengue fever is compulsory (Ordinance
MH/MO no. 204 (2016 February 17th)). Thus, we can assume:
·
An infected human should look for medical treatment
when he/she will become clinically ill;
· Only a fraction of those humans that are clinically ill will be reported to sanitary authorities. The remaining fraction (I) will not look for medical help, even if the clinical symptoms and signs appear; or (II) will not be correctly reported in the hospitals. Now, the equations related to infected categories in system (1) are:
The terms that include
Where
The data provided by Brazilian Ministery of Health represents the
reported cases per year. Thus, since time scale considered in this work is day,
it was estimated an average of human reported cases per day for each year
(dividing the total from each year by 365). Finally, model considers a
normalized population (all population is constant). As a last step, we have to
divide each rate of human reported cases per day by the official population size
of Brazil. The estimated population size of Brazil is available on Brazilian
Institute of Geography and Statistics (BIGS) website [17].
In order to fit and compare the model output to real data, it was also
calculated a normalized average of reported cases per day from each 365 days of
simulation. This simulation was run considering 50 years and the obtained curve
was fitted by simple handling along the time-axis (for instance, we could assume
the initial day
4.
Numerical Simulation
In order to analyze the dynamics of our model, we simulated the set of equations from (1) considering the parameters on Table 1. It was focused on human reported rate, since the real data can be used as reference (Figure 2) illustrate the reported human cases rate and the trend indicated by the simulation (yearly average).
For the evaluation of the impact of vaccination, it was supposed that
the vaccination campaign would start by 2018. Then, a vaccination rate
Some comments can be introduced about the dynamics presented in Figure
3. Note that, for a vaccination rate of
5.
Analysis of
Vaccination Impact
Considering the evaluation of the efficacy and cost-effectiveness of a
dengue vaccination (
|
(4) |
where
In the case of
|
(5) |
Here, the result presented in Figure 4 deserve for some clarification.
As described before, (Figure 4) informs how many
vaccines were needing to avoid one reported case over time. For example,
considering 2 years after the introduction of the vaccination (2020 year),
Figure 4 indicates that it was necessary around
6.
Discussion
In this work, the impact of Dengue vaccination was evaluated considering
a mathematical model adapted from [1], which in
turn evaluated the Dengue fever dynamics based on a multi-strain model. Here,
the parameters values were modified to day time scale and their values were
changed according to Brazilian scenery. The study presented here provided a new
approach for impact of Dengue vaccine. Since Dengue fever is caused by 4 serotypes,
the usual mathematical models that consider the Dengue transmission by a
generic virus cannot be the best option. Due to this fact, a multi-strain model
was adapted to evaluate the Dengue dynamics and the impact of vaccination on
it. To the best of our knowledge, the work presented here is one of the first
in which evaluated by mathematical modeling the impact of Dengue vaccination
considering a multi-strain model. Also, considering that such vaccine has a
short period of cross-immunity and the possibility of vaccinated individuals
become serotype 2 infected, the mathematical modeling of this phenomena was
very useful to aid in the comprehension of this dynamics. The results presented
in Figure 3 indicates how the Dengue dynamics would be modified if the vaccine
described by World Health Organization is introduced. It is important to
highlight that the immunization effect of such vaccine is valid only to
individuals from category
Finally, it should be noted that in multi-strain models like the current one [28] showed that the strain which is only directly transmitted can invade the endemic state of the strain with mixed transmission. The endemic state of the first strain, however, is neutrally stable to invasion by the second strain.
The study presented here provided a general approach about how the
Dengue dynamics can change when the vaccine is introduced. In addition, it also
helps to understand how the densities of each infected category are modified
over time. Since the vaccinated individual
7. Acknowledgments
This work has been supported by the project ZikaPLAN, funded by the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. 734584, by LIM01-HFMUSP, CNPq and FAPESP.
Figure 1: Compartment model and flowchart. The non-continuous line indicates the
influence of a category on the indicated flux. For instance, influences on the
transition of
Figure 2: Dynamics of reported human cases rate. The available real data are from
2000 to 2017 (bars) and our model was fitted for the same period (line). Observe
that the real data has increased over time and reaches a peak in 2016. Source: Brazilian
Ministry of Health (SINAN) and BIGE.
Figure 3: Impact of vaccination on dynamics of reported human cases rate. The
graph represents a scenery where the vaccination starts in 2018 (the simulation
estimated that the average density of total reported cases per day was around
Figure 4: Result of the
simulations of expression (4) over time, according to each strategy.
Parameter |
Biological meaning |
Value |
Unit |
Source |
μ |
Natural mortality rate |
3.67×10-5 |
day-1 |
(Brazilian Institute of Geography and Statistics, 2013) [17] |
γ |
Recovery rate |
1.43×10-1 |
day-1 |
(Halstead, 1990) [18] |
βt |
Infection rate |
2.85×10-1 |
human×day-1 |
(Fergurson, et al., 1999)[19] |
α |
Temporary cross-immunity rate |
5.48×10-5 |
day-1 |
(Matheus, et al., 2005) [20] |
ϕ |
Ratio of secondary infections contributing to force of infection |
∈0, 3 |
dimensionless |
(Aguiar, et al., 2008)[21] |
ρ |
Import parameter |
0 |
dimensionless |
(Nagao & Koelle, 2008)[22] |
υ |
Vaccination rate |
variable |
day-1 |
- |
ψ |
Infection rate to y2 |
variable |
day-1 |
- |
τ |
Interval between vaccine doses |
1.82×102 |
day |
(World Health Organization, 2017) [23,24] |
η |
Proportion of reported cases |
5.0×10-2 |
dimensionless |
Silva et al. (2Table 1: Parameters and their biological meaning adapted from [1].016) [25] |
Table 1: Parameters and their biological meaning adapted from [1].
Year |
Total of reported cases (Brazilian Ministry of Health, 2018) |
Day average |
Total Brazilian population (BIGS, 2013) |
Normalized day average |
Log (Normalized day average) |
2000 |
506 |
1.39 |
173448346 |
7.99E-09 |
-8.1 |
2001 |
1938 |
5.31 |
175885229 |
3.02E-08 |
-7.52 |
2002 |
3786 |
10.37 |
178276128 |
5.82E-08 |
-7.24 |
2003 |
1285 |
3.52 |
180619108 |
1.95E-08 |
-7.71 |
2004 |
859 |
2.35 |
182911487 |
1.29E-08 |
-7.89 |
2005 |
1185 |
3.25 |
185150806 |
1.75E-08 |
-7.76 |
2006 |
1425 |
3.9 |
187335137 |
2.08E-08 |
-7.68 |
2007 |
1453 |
3.98 |
189462755 |
2.10E-08 |
-7.68 |
2008 |
1073 |
2.94 |
191532439 |
1.53E-08 |
-7.81 |
2009 |
1376 |
3.77 |
193543969 |
1.95E-08 |
-7.71 |
2010 |
2978 |
8.16 |
195497797 |
4.17E-08 |
-7.38 |
2011 |
3129 |
8.57 |
197397018 |
4.34E-08 |
-7.36 |
2012 |
2853 |
7.82 |
199242462 |
3.92E-08 |
-7.41 |
2013 |
2928 |
8.02 |
201032714 |
3.99E-08 |
-7.4 |
2014 |
2742 |
7.51 |
202768562 |
3.70E-08 |
-7.43 |
2015 |
4720 |
12.93 |
204450649 |
6.33E-08 |
-7.2 |
2016 |
1475741 |
4043.13 |
206081432 |
1.96E-05 |
-4.71 |
2017 |
24742 |
677.87 |
20766092 |
3.26E-06 |
-5.49 |
Table 2: Human reported cases in Brazil: average of the normalized rate per day for each year.
- Santos MAF (2012) Rich dynamics in multi-strain models: non-linear dynamics and deterministic chaos in dengue fever epidemiology. Lisbon: Lisbon University. PhD Thesis 2012.
- Boccia TMQR, Burattini MN, Coutinho FAB, Massad E (2013) Will people change their vector-control practices in the presence of an imperfect dengue vaccine? Epidemiology and Infection 142: 625-633.
- Struchiner CJ, Rocklöv J, Wilder-Smith A, Massad E (2015) Increasing Dengue Incidence in Singapore over the Past 40 Years: Population Growth, Climate and Mobility. PLoS ONE 8: e0136286.
- Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, et al. (2013) The global distribution and burden of dengue. Nature 496: 504-507.
- Scott LJ (2016) Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease. Drugs 76: 1301-1312.
- Wilder-Smith A, Massad E (2016) Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. Expert Rev Vaccines 15: 437-441.
- Massad E (2004) Introdução. Massad E, Menezes RX, Silveira PSP, Ortega NRS, eds. Métodos Quantitativos em Medicina. Barueri: Manole: 570.
- Maier SB, Huang X, Massad E, Amaku M, Burattini MN, et al. (2017) Analysis of the optimal vaccination age for dengue in Brazil with a tetravalent dengue vaccine. Math Biosci 294: 15-32.
- Flasche S, Jit M, Rodríguez-Barraquer I, Coudeville L, Recker M, et al. (2016) The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS Med 13: e1002181.
- Luz PM, Grinsztejn B, Galvani AP (2009) Disability adjusted life years lost to dengue in Brazil. Trop Med Int Health 14: 237-246.
- Ministry of Health (Brazil) (2018). DATASUS - Information Technology at the service of SUS (only in portuguese).
- Gluber DJ (2011) Dengue, Urbanization and Globalization: The Unholy Trinity of the 21st Century. Trop Med Health 39: 3-11.
- Tozan Y (2016) Current issues in the economics of vaccination against dengue. Expert Rev Vaccines 15: 519-528.
- Amaku M, Coudeville L, Massad E (2012) Designing a vaccination strategy against dengue. Rev Inst Med Trop Sao Paulo 18: S18-S21.
- Raimundo SM, Amaku M, Massad E (2015) Equilibrium Analysis of a Yellow Fever Dynamical Model with Vaccination. Computational and Mathematical Methods in Medicine, Article ID 482091.
- Raimundo SM, Yang HM, Massad E (2016) Modeling vaccine preventable vector-borne infections: yellow fever as a case study. Journal of Biological Systems 24: 193-216.
- Brazilian Institute of Geography and Statistics (BIGS) (2013) In 2012, life expectancy at birth was 74.6 years.
- Halstead SB (1990) Dengue. Warren KS, Mahmoud AAF, eds. Tropical and Geographical Medicine. New York: McGraw-Hill 1990: 675-684.
- Fergurson N, Anderson R, Gupta S (1999) The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens. Proc Natl Acad Sci USA 96: 790-794.
- Matheus S, Deparis X, Labeau B, Lelarge J, Morvan J, et al. (2005) Discrimination between primary and secondary dengue virus infection by an immunoglobulin G avidity test using a single acute-phase serum sample. J Clin Microbiol 43: 2793-2797.
- Aguiar M, Kooi B, Stollenwerk N (2008) Epidemiology of Dengue Fever: A Model with Temporary Cross-Immunity and Possible Secondary Infection Shows Bifurcations and Chaotic Behaviour in Wide Parameter Regions. Math Model Nat Phenom 3: 48-70.
- Nagao Y, Koelle K (2008) Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever. Proceedings of National Academy of Sciences 105: 2238-2243.
- World Health Organization (2017) Dengue and severe dengue.
- World Health Organization (2017) Immunization, Vaccines and Biologicals. Updated Questions and Answers related to the dengue vaccine Dengvaxia® and its use.
- Silva M, Rodrigues MS, Paploski I, Kikuti M, Kasper AM, et al. (2016) Accuracy of Dengue Reporting by National Surveillance System, Brazil. Emerg Infec Dis 22: 336-339.
- Shimozako HJ, Wu J, Massad E (2017) Mathematical modelling for Zoonotic Visceral Leishmaniasis dynamics: A new analysis considering updated parameters and notified human Brazilian data. Infectious Disease Modelling 2: 143-160.
- Shimozako HJ, Wu J, Massad E (2017) The Preventive Control of Zoonotic Visceral Leishmaniasis: Efficacy and Economic Evaluation. Computational and Mathematical Methods in Medicine 2017.
- Brenan R, Drake JM, Rohani P (2010) A general multi-strain model with environmental transmission: invasion conditions for the disease-free and endemic states. J Theor Biol 264: 729-736.
- Halstead SB (2003) Neutralization and antibody-dependent enhancement of Dengue Viruses. Adv Virus Res 60: 421-467.
- United Nations (2010) World Urbanization Prospects: The 2009 Revision Population Database. New York: United Nations. Department of Economic and Social Affairs/Population Division.
- Wilder-Smith A, Preet R, Renhorn KE, Ximenes RA, Rodrigues LC, et al. (2017) ZikaPLAN: Zika Preparedness Latin American Network. Global Health Action 10: 1398485.